Compounds > temozolomide
Page last updated: 2024-11-04

temozolomide and Argentaffinoma

temozolomide has been researched along with Argentaffinoma in 16 studies

Research Excerpts

ExcerptRelevanceReference
"Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking."9.69Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. ( Amoroso, V; Berruti, A; Brizzi, MP; Colao, A; Faggiano, A; Fazio, N; Ferolla, P; Ghizzoni, S; Giuffrida, D; Houchard, A; Ibrahim, T; La Salvia, A; Marconcini, R; Mazzanti, P; Spada, F; Vaccaro, V; Volante, M, 2023)
"Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)."9.12Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006)
"MGMT deficiency, measured by immunohistochemistry, is more common in pancreatic neuroendocrine tumors than in carcinoid tumors as is treatment response to temozolomide-based therapy."7.75O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Frauenhoffer, C; Fuchs, CS; Hooshmand, S; Hornick, JL; Kulke, MH; Meyerhardt, JA; Redston, MS; Ryan, DP; Stuart, K, 2009)
"A retrospective analysis of the toxicity and efficacy of temozolomide in advanced neuroendocrine tumors."7.74Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. ( Dunder, K; Ekeblad, S; Eriksson, B; Granberg, D; Janson, ET; Kindmark, H; Kozlovacki, G; Oberg, K; Orlefors, H; Sigurd, M; Skogseid, B; Sundin, A; Welin, S, 2007)
"Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking."5.69Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. ( Amoroso, V; Berruti, A; Brizzi, MP; Colao, A; Faggiano, A; Fazio, N; Ferolla, P; Ghizzoni, S; Giuffrida, D; Houchard, A; Ibrahim, T; La Salvia, A; Marconcini, R; Mazzanti, P; Spada, F; Vaccaro, V; Volante, M, 2023)
"Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease."5.40Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. ( Abbasi, S; Albaba, H; Kashashna, A, 2014)
"Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)."5.12Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006)
" The authors report a case of radiation recall resulting from an interaction between radiation delivered during a fluoroscopically guided hepatic chemoembolization for treatment of metastatic carcinoid tumor and the oral chemotherapeutic agents capecitabine and temozolomide administered 7 weeks later."3.80Radiation recall after a transarterial hepatic chemoembolization. ( Sands, MJ; Wunderle, KA, 2014)
"MGMT deficiency, measured by immunohistochemistry, is more common in pancreatic neuroendocrine tumors than in carcinoid tumors as is treatment response to temozolomide-based therapy."3.75O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Frauenhoffer, C; Fuchs, CS; Hooshmand, S; Hornick, JL; Kulke, MH; Meyerhardt, JA; Redston, MS; Ryan, DP; Stuart, K, 2009)
"A retrospective analysis of the toxicity and efficacy of temozolomide in advanced neuroendocrine tumors."3.74Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. ( Dunder, K; Ekeblad, S; Eriksson, B; Granberg, D; Janson, ET; Kindmark, H; Kozlovacki, G; Oberg, K; Orlefors, H; Sigurd, M; Skogseid, B; Sundin, A; Welin, S, 2007)
"Everolimus is an appropriate first-line choice for somatostatin receptor negative tumors and for any patients with progressive disease."2.66Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. ( Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D, 2020)
"Pulmonary carcinoids (PCs) are rare tumors."2.52Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. ( Baudin, E; Caplin, ME; Ferolla, P; Filosso, P; Garcia-Yuste, M; Lim, E; Oberg, K; Pelosi, G; Perren, A; Rossi, RE; Travis, WD, 2015)
"Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease."1.40Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. ( Abbasi, S; Albaba, H; Kashashna, A, 2014)
"Temozolomide was given on 5 consecutive days every 4 weeks."1.39Effect of temozolomide in patients with metastatic bronchial carcinoids. ( Antonodimitrakis, P; Crona, J; Eriksson, B; Fanola, I; Granberg, D; Lindholm, DP; Öberg, K, 2013)
"Temozolomide is a well-tolerated oral chemotherapy in patients with malignant DET, including those who have already received treatment."1.35Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. ( Couvelard, A; Faivre, S; Hammel, P; Hentic, O; Larroque, B; Lévy, P; Maire, F; Raymond, E; Ruszniewski, P; Yapur, L; Zappa, M, 2009)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (25.00)29.6817
2010's7 (43.75)24.3611
2020's5 (31.25)2.80

Authors

AuthorsStudies
Hiddinga, B1
Zwaenepoel, K1
Janssens, A1
Van Meerbeeck, J1
Pauwels, P1
Sun, F1
Grenert, JP1
Tan, L1
Van Ziffle, J1
Joseph, NM1
Mulvey, CK1
Bergsland, E1
Ferolla, P2
Berruti, A1
Spada, F1
Brizzi, MP1
Ibrahim, T1
Marconcini, R1
Giuffrida, D1
Amoroso, V1
La Salvia, A1
Vaccaro, V1
Faggiano, A1
Colao, A1
Volante, M1
Ghizzoni, S1
Mazzanti, P1
Houchard, A1
Fazio, N1
Papaxoinis, G1
Kordatou, Z1
McCallum, L1
Nasralla, M1
Lamarca, A1
Backen, A1
Nonaka, D1
Mansoor, W1
Uprety, D1
Halfdanarson, TR1
Molina, JR1
Leventakos, K1
Crona, J1
Fanola, I1
Lindholm, DP1
Antonodimitrakis, P1
Öberg, K3
Eriksson, B2
Granberg, D2
Wunderle, KA1
Sands, MJ1
Abbasi, S1
Kashashna, A1
Albaba, H1
Caplin, ME1
Baudin, E1
Filosso, P1
Garcia-Yuste, M1
Lim, E1
Pelosi, G1
Perren, A1
Rossi, RE1
Travis, WD1
Kulke, MH2
Hornick, JL1
Frauenhoffer, C1
Hooshmand, S1
Ryan, DP2
Enzinger, PC2
Meyerhardt, JA1
Clark, JW2
Stuart, K2
Fuchs, CS2
Redston, MS1
Maire, F1
Hammel, P2
Faivre, S2
Hentic, O2
Yapur, L1
Larroque, B1
Couvelard, A1
Zappa, M1
Raymond, E2
Lévy, P1
Ruszniewski, P2
Pregun, I1
Bodoky, G1
Rácz, K1
Tulassay, Z1
Reidy-Lagunes, D1
Thornton, R1
Neuzillet, C1
Muzikansky, A1
Vincitore, M1
Michelini, A1
Ekeblad, S1
Sundin, A1
Janson, ET1
Welin, S1
Kindmark, H1
Dunder, K1
Kozlovacki, G1
Orlefors, H1
Sigurd, M1
Skogseid, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Overall Survival and Progression Free Survival of Patients With Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV[NCT03998332]132 participants (Actual)Observational2002-01-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for temozolomide and Argentaffinoma

ArticleYear
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
    Current treatment options in oncology, 2020, 08-29, Volume: 21, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecita

2020
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoscopy; Carboplatin; Carcinoid Heart Disease;

2015
[Carcinoid tumors].
    Orvosi hetilap, 2010, Nov-14, Volume: 151, Issue:46

    Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Biomarkers, Tumor; Bronchial Neoplasms; Carcinoid Tumo

2010
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
    Current oncology reports, 2012, Volume: 14, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbaz

2012
New treatment options with cytotoxic agents in neuroendocrine tumours.
    Targeted oncology, 2012, Volume: 7, Issue:3

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Clinical Trials as

2012

Trials

2 trials available for temozolomide and Argentaffinoma

ArticleYear
Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
    Neuroendocrinology, 2023, Volume: 113, Issue:3

    Topics: Carcinoid Tumor; Female; Humans; Male; Neuroendocrine Tumors; Pilot Projects; Prospective Studies; T

2023
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An

2006

Other Studies

9 other studies available for temozolomide and Argentaffinoma

ArticleYear
Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
    Oncotarget, 2022, Volume: 13

    Topics: Anaplastic Lymphoma Kinase; Biomarkers; Carcinoid Tumor; Carcinoma, Neuroendocrine; DNA; DNA Methyla

2022
Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.
    JCO precision oncology, 2022, Volume: 6

    Topics: Carcinoid Tumor; Humans; Immunotherapy; Lung Neoplasms; Temozolomide

2022
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
    Neuroendocrinology, 2020, Volume: 110, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Comb

2020
Effect of temozolomide in patients with metastatic bronchial carcinoids.
    Neuroendocrinology, 2013, Volume: 98, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bronchial Neoplasms; Carcinoid Tu

2013
Radiation recall after a transarterial hepatic chemoembolization.
    Journal of vascular and interventional radiology : JVIR, 2014, Volume: 25, Issue:7

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor;

2014
Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
    Pancreas, 2014, Volume: 43, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoid Tumor; Cell Dif

2014
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-01, Volume: 15, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Disease-Free Survival; Female; Huma

2009
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.
    Neuroendocrinology, 2009, Volume: 90, Issue:1

    Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Digesti

2009
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10

    Topics: Aged; Bronchial Neoplasms; Carcinoid Tumor; Dacarbazine; Female; Hematologic Diseases; Humans; Male;

2007